Latest Cancer vaccine Stories

Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors. In early studies, 60 percent of tumor-burdened mice were cured in fewer than three months and...

ATLANTA, March 12, 2012 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta - based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced receipt of an "Allowed to Proceed" notice from the U.S. Food and Drug Administration (FDA) for human clinical testing of its granulocyte-macrophage colony stimulating factor (GM-CSF) -adjuvanted DNA/MVA vaccine. The Phase 1 trial is being sponsored by the National...

HOUSTON, March 8, 2012 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced that it has raised $20 million in a Series B financing. The funding will be used to advance its lead CaspaCIDe(TM) and DeCIDe(TM) programs through Phase 2 clinical development. The additional funding strengthens Bellicum's balance sheet with $26 million of committed capital, including a $6.1 million award from the Cancer Prevention and Research Institute of Texas (CPRIT). Current and new investors...

The first therapeutic cancer vaccine has now been approved by the FDA, and a diverse range of therapeutic cancer vaccines directed against a spectrum of tumor-associated antigens are currently being evaluated in clinical trials, according to a review published March 6 in the Journal of the National Cancer Institute. The tumor microenvironment and other immunosuppressive entities can potentially limit the efficacy of vaccines. To counteract this, the use of vaccines with immune checkpoint...

HONG KONG, March 6, 2012 /PRNewswire-Asia/ -- CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Company") today announced that the FDA (U.S. Food and Drug Administration) has granted clearance for its subsidiary Polynoma LLC ("Polynoma")'s Investigational new drug (IND) application, allowing it to proceed with Phase III clinical testing of its melanoma vaccine. One of A Few Asian Companies Cleared by FDA for Phase III Clinical Trial This makes CK Life Sciences one of a...

ALBANY, New York, February 16, 2012 /PRNewswire/ -- New Report Added in ResearchMoz Reports DatabaseVaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts) [http://www.researchmoz.com/vaccine-production-trends-techniques-key-players-spending-estimates-and-forecasts-report.html ] The considerable revenue growth in the vaccine market over the past ten years suggests the amount of vaccine production and the techniques of vaccine production...

Majority of Patients Treated Develop Strong, Lasting Immune Responses Researchers at the Perelman School of Medicine and the Abramson Cancer Center at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient’s own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer. More than 85 percent of patients treated appear to have...

The findings were published online in Cancer Research Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumors. The discovery has been patented and there are plans to develop the vaccine for clinical use...

TUEBINGEN, Germany, January 24, 2012 /PRNewswire/ -- Study shows a consistent association between immune response to IMA910 and all clinical endpoints and an excellent tolerability profile immatics' unique XPRESIDENT(TM) platform delivers a second promising therapeutic cancer vaccine candidate immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced positive...

WORCESTER, Mass. and TORONTO, Jan. 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a detailed interview conducted at the BioTech Showcase 2012 during last week's JPMorgan Healthcare Conference in San Francisco with Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., regarding the Antigen Express breast cancer vaccine, is available on the Stock News Now website (www.stocknewsnow.com) and on the Generex...